ISRCTN53835788 https://doi.org/10.1186/ISRCTN53835788

# Medium/long term effect of travoprost on the intraocular pressure (IOP) in normal tension glaucoma (NTG)

| | | |
|---|---|---|
| **Submission date**<br>30/09/2005 | **Recruitment status**<br>No longer recruiting | [_] Prospectively registered<br>[_] Protocol<br>[_] Statistical analysis plan<br>[X] Results<br>[_] Individual participant data |
| **Registration date**<br>30/09/2005 | **Overall study status**<br>Completed | |
| **Last Edited**<br>03/06/2008 | **Condition category**<br>Eye Diseases | |

**Plain English summary of protocol**
Not provided at time of registration

## Contact information

**Type(s)**
Scientific

**Contact name**
Mr G.S. Ang

**Contact details**
Senior House Officer
Department of Ophthalmology
Norfolk and Norwich University Hospital NHS Trust
Colney
Norwich
United Kingdom
NR4 7UY

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**
N0547147995

# Study information

### Scientific Title

### Study objectives
Travoprost is a new prostaglandin analogue recently approved for treatment of ocular hypertension and glaucoma.

### Ethics approval required
Old ethics approval format

### Ethics approval(s)
Not provided at time of registration

### Study design
Randomised controlled trial

### Primary study design
Interventional

### Secondary study design
Randomised controlled trial

### Study setting(s)
Not specified

### Study type(s)
Treatment

### Participant information sheet

### Health condition(s) or problem(s) studied
Eye Diseases: Glaucoma

### Interventions
Prospective randomised controlled observer blinded clinical trial.

### Intervention Type
Other

### Phase
Not Specified

### Primary outcome measure
The primary clinical outcome measure is diurnal IOP at follow up phasing: the major comparison is to be made between the IOP for travoprost treatment group and for the non-treatment group.

### Secondary outcome measures

Not provided at time of registration

### Overall study start date
01/04/2004

### Completion date
01/06/2006

## Eligibility

### Key inclusion criteria
Adults with normal tension glaucoma.

### Participant type(s)
Patient

### Age group
Adult

### Sex
Not Specified

### Target number of participants
25-30 patients

### Key exclusion criteria
1. Patients on systemic medication
2. Patients who have undergone intraocular eye surgery

### Date of first enrolment
01/04/2004

### Date of final enrolment
01/06/2006

## Locations

### Countries of recruitment
England

United Kingdom

### Study participating centre
**Senior House Officer**
Norwich
United Kingdom
NR4 7UY

# Sponsor information

**Organisation**
Department of Health

**Sponsor details**
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL
+44 (0)20 7307 2622
dhmail@doh.gsi.org.uk

**Sponsor type**
Government

**Website**
http://www.dh.gov.uk/Home/fs/en

# Funder(s)

**Funder type**
Government

**Funder Name**
East Norfolk and Waveney Research Consortium - Norfolk and Norwich University Hospital /Norwich PCT

# Results and Publications

**Publication and dissemination plan**
Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**
Not provided at time of registration

**Study outputs**

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
| --- | --- | --- | --- | --- | --- |
| Results article | Results | 01/08/2008 | | Yes | No |